Home › Genelux announces promising data from two phase I trials of GL-ONC1...
 

Keywords :   


Genelux announces promising data from two phase I trials of GL-ONC1...

2015-05-28 22:50:38| Logistics - Topix.net

Genelux Corporation, a clinical-stage biopharmaceutical company focused on the development of vaccinia virus for oncolytic immunotherapy, today announced that data from two Phase I trials evaluating its lead oncolytic virotherapy GL-ONC1 in head and neck cancer and malignant pleural mesothelioma demonstrate a favorable safety profile and support further investigation of the therapy in both indications. The results will be presented by lead investigators from Memorial Sloan Kettering Cancer Center and UC San Diego Moores Cancer Center at the upcoming 2015 American Society of Clinical Oncology Annual Meeting, being held May 29-June 2 in Chicago, IL.

Tags: of data phase trials

Category:Transportation and Logistics

Latest from this category

All news
»
10.05Argentines strike against spending cuts
10.05Two Daytona Waste Pro Drivers Jump into Action After Car Crash
10.05Together for Safer Roads and National Waste & Recycling Association Announce New Participants in FOCUS on Fleet Safety Training
10.05Start Your Day with Tom Gratz, Sales Manager USA, Hitachi Zosen Inova
10.05Scotlands Road to Circularity and Its Water Utilitys Sustainability Story
10.05Simplified Environmental Solutions (SES) Expands Zero Waste to Landfill Operations to Salt Lake City and Kansas City
10.05Zero Waste Lunch at WasteExpo Showcases Potential of Leftover, Undesirable Foods
10.05Rubicon Announces Sale of Fleet Technology Business Unit
More »